Published • loading... • Updated
Incyte Trial Data Support New First-Line Approach in Lymphoma
Summary by MyChesCo
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Incyte Trial Data Support New First-Line Approach in Lymphoma
WILMINGTON, DE — Incyte (Nasdaq: INCY) reported Phase III trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death in patients with previously untreated high-risk diffuse large B-cell lymphoma and high-grade B-cell lymphoma, potentially positioning the combination as a new frontline treatment option. The findings from the frontMIND study were presented during a…
Father's Day SaleGet 40% off Vantage subscriptions for yourself or a friend.Get Started
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
